مقاله انگلیسی رایگان در مورد ارتباط سنی با نشانه های بالینی خشکی چشم در مطالعه ارزیابی و مدیریت خشکی چشم – الزویر 2023

 

مشخصات مقاله
ترجمه عنوان مقاله ارتباط سنی با علائم و نشانه های بالینی خشکی چشم در مطالعه ارزیابی و مدیریت خشکی چشم (DREAM)
عنوان انگلیسی مقاله Age Associations with Dry Eye Clinical Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study
نشریه الزویر
انتشار مقاله سال 2023
تعداد صفحات مقاله انگلیسی 10 صفحه
هزینه دانلود مقاله انگلیسی رایگان میباشد.
مقاله بیس این مقاله بیس نمیباشد
نمایه (index) JCR – Master Journal List – Scopus – ISC – Medline
نوع مقاله ISI
فرمت مقاله انگلیسی  PDF
ایمپکت فاکتور(IF)
5.470 در سال 2022
شاخص H_index 267 در سال 2022
شاخص SJR 3.913 در سال 2022
شناسه ISSN 0161-6420
شاخص Quartile (چارک) Q1 در سال 2022
فرضیه ندارد
مدل مفهومی ندارد
پرسشنامه ندارد
متغیر ندارد
رفرنس دارد
رشته های مرتبط پزشکی
گرایش های مرتبط چشم پزشکی
نوع ارائه مقاله
ژورنال
مجله  علم چشم پزشکی – Ophthalmology Science
دانشگاه Department of Computer Science, Babasaheb Bhimrao Ambedkar University, Lucknow (UP), India
کلمات کلیدی رایانش ابری سیار – بارگذاری توزیع شده – تعادل نش – قیمت هرج و مرج – همگرایی
کلمات کلیدی انگلیسی Mobile cloud computing – distributed offloading – Nash equilibrium – price of anarchy – convergence
شناسه دیجیتال – doi
https://doi.org/10.1016/j.xops.2023.100270
کد محصول e17404
وضعیت ترجمه مقاله  ترجمه آماده این مقاله موجود نمیباشد. میتوانید از طریق دکمه پایین سفارش دهید.
دانلود رایگان مقاله دانلود رایگان مقاله انگلیسی
سفارش ترجمه این مقاله سفارش ترجمه این مقاله

 

فهرست مطالب مقاله:
Abstract
Methods
Results
Discussion
Footnotes and Disclosures
References

بخشی از متن مقاله:

Abstract

Purpose: To evaluate how increasing age is associated with dry eye disease (DED) signs and symptoms in the Dry Eye Assessment and Management (DREAM) study. This study was undertaken to better understand how DED signs and symptoms differ across decades of life with goals to help assess detection and treatment of DED.

Design: Secondary analysis of the DREAM study.

Subjects: One hundred twenty, 140, 185, and 90 participants aged < 50, 50 to 59, 60 to 69, and  70 years, respectively

Methods: We performed a secondary analysis of data from the DREAM study, a multicenter randomized clinical trial, to evaluate the effect of omega-3 fatty acid supplementation for the treatment of DED. At baseline, 6 months, and 12 months follow-up, participants underwent an assessment of DED symptoms and signs using Ocular Surface Disease Index, Brief Pain Inventory, tear break-up time (TBUT) (in seconds), Schirmer test with anesthesia (mm/5 minutes), conjunctival staining, corneal staining, meibomian gland dysfunction evaluation, and tear osmolarity (mOsm/l). Multivariable generalized linear regression models were used to compare DED symptoms and signs across the 4 age groups among all participants and by sex

Methods

This is a secondary analysis of data from the DREAM study (ClinicalTrials.gov identifier, NCT02128763). The results of the DREAM study were previously published and showed that the active treatment group that received omega-3 supplementation did not show a significant difference in DED signs and symptoms compared with the placebo group that received olive oil pills.34 Briefly, 535 patients with moderate to severe DED and who were  18 years of age were enrolled in the study. All enrolled patients had moderate to severe DED symptoms for at least 6 months before the screening visit, use or desired use of artificial tears twice daily in the 2 weeks before the screening visit, and an Ocular Surface Disease Index (OSDI) score of 25 to 80 at the screening visit and 21 to 80 at the baseline visit. Full details on the inclusion and exclusion criteria and outcome measures can be found in the previously published primary results of the DREAM study.34 The study was approved by the institutional review board/ethics committee at each center (centers listed in Credit Roster for the DREAM study, available at www.opththalmologyscience.org), followed the tenets of the Declaration of Helsinki, and written informed consent was obtained from all patients.

Results

Table 1 shows the comparison of baseline characteristics among the 4 age groups of DREAM participants. Across 4 age groups (< 50, 50e59, 60e69,  70 years), older age groups had a higher percent of White race (67.5% vs. 69.3% vs. 78.9% vs. 82.2%, P < 0.001) and a higher percent of non-Hispanic or Latino ethnicity (77.5% vs. 82.1% vs. 91.9% vs. 94.4%, P < 0.001). Older age groups had a lower percent of never smokers (80.8% vs. 69.3% vs. 66.5% vs. 55.6%, P < 0.001), a higher percent of self-reported ongoing peripheral artery disease (7.5% vs. 3.6% vs. 10.8% vs. 14.4%, P ¼ 0.002), and a higher percent of hypertension (12.5% vs. 16.4% vs. 20.0% vs. 21.1%, P < 0.001). Older age groups also had a higher percent with osteoarthritis (5.8% vs. 15.0% vs. 33.5% vs. 48.9%, P < 0.001), with hypercholesteremia (8.3% vs. 29.3% vs. 43.2% vs. 44.4%, P < 0.001), and taking statin medications (6.7% vs. 17.9% vs. 31.9% vs. 41.1%, P < 0.001) and a higher mean summary component measure of mental health (49.6 vs. 50.8 vs. 54.5 vs. 54.1, P < 0.001). Regarding treatment for dry eye, older age groups had a higher percent of using tears or gel (71.7% vs. 73.6% vs. 83.2% vs. 90.0%, P ¼ 0.002) and using more cyclosporine drops (10.0% vs. 20.7% vs. 23.2% vs. 23.3%, P ¼ 0.02) and warm liquid soaks (14.2% vs. 16.4% vs. 27.6% vs. 25.6%, P ¼ 0.01). They also used more other dry eye treatments beyond artificial tears or gel, cyclosporine drops, warm lid soaks, lid scrubs, or baby shampoo (21.7% vs. 30.7% vs. 38.9% vs. 38.9%, P ¼ 0.009).

دیدگاهتان را بنویسید

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *

دکمه بازگشت به بالا